Every organ that travels from donor to recipient is racing a clock the moment blood flow stops. Biologic Hemoglobin Oxygen Carrier (BHOC) technology is one of the more promising attempts to slow that clock — and almost no patient or care partner has ever heard of it.
Cold ischemia — the time an organ spends without blood flow between recovery and transplant — is the single most damaging window in the entire transplant process, and it's also the namesake of this foundation for a reason. The longer that window stretches, the more cellular damage accumulates before the organ is ever reconnected to a body.
BHOC technology is built around synthetic or modified hemoglobin-based carriers designed to deliver oxygen to tissue independent of a beating heart or intact vasculature. In plain terms: it's a way to keep an organ's cells supplied with oxygen during the exact window where they'd otherwise be starving for it. That's a fundamentally different tool than anything currently standard in organ preservation, which mostly relies on cold storage alone to slow metabolic damage rather than actively interrupting it.
Cold storage slows the damage. Oxygen-carrying technology is one of the few approaches trying to stop it from happening at all.
This is not a secret. It's published, presented, and discussed — but almost exclusively among transplant surgeons, organ preservation researchers, and the companies developing the technology. It essentially never makes it into a conversation with the person actually waiting for an organ, or the care partner who's about to spend the next year managing their recovery.
That gap matters for a simple reason: technology that could shorten viable preservation windows, expand the geographic range organs can travel, and reduce delayed graft function isn't just a surgical curiosity. It's directly relevant to whether a specific patient in a specific region gets offered a specific organ at all. Patients deserve to understand what's being worked on to solve the problem that keeps them waiting — not just be told the waitlist is long.
Organs preserved longer and better could mean a wider pool of viable offers reaching people who are currently ruled out by distance or timing alone.
Delayed graft function — a major driver of a harder first weeks post-transplant — is closely tied to how much damage an organ sustained before transplant. Better preservation is a care partner's problem too.
Novel preservation technology faces a slow, expensive, heavily regulated path to clinical adoption — and no organized patient constituency is currently pushing for it to move faster.
Cold Ischemia Foundation is engaging directly with BHOC researchers and developers — not to promote a product, but to translate what this technology is, what it isn't, and why it deserves a place in the conversation patients and care partners are having about the future of transplant medicine. That means plain-language explanation instead of a surgical journal abstract, and outreach to the regulatory and clinical bodies who decide whether emerging preservation technology reaches the people waiting for it.
This is early-stage, evolving technology. It is not yet standard of care, and no patient should expect it to change their current transplant timeline. The goal here is awareness and informed conversation — not premature promises.
If preservation technology is going to move faster from lab to standard practice, it will be because the people who actually have something at stake — patients, care partners, living donors — understood it well enough to ask their transplant centers about it. That's the conversation this page exists to start.